BeiGene's LBL-007/tislelizumab colorectal cancer trial posts results
The Phase 1b/2 study testing alcestobart with tislelizumab and standard therapy in colorectal cancer has posted results.
BeiGene's colorectal cancer trial for alcestobart (LBL-007) has posted results this week.
- A Phase 1b/2, randomized, open-label study (NCT05609370) is investigating alcestobart plus tislelizumab in combination with bevacizumab and fluoropyrimidine, versus bevacizumab plus fluoropyrimidine, as maintenance therapy in patients with unresectable or metastatic microsatellite stable or mismatch repair proficient colorectal cancer.1 The trial is sponsored by BeiGene, with primary completion listed as 2025-05-23 and results first posted on 2026-06-30.1 The study enrolled 113 participants, and its overall status is active, not recruiting.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.